Objective To explore the efficacy of Jiawei Buyang Huanwu Tang combined with western medicine in the treatment of patients with idiopathic membranous nephropathy. Methods A total of 120 patients with idiopathic membranous nephropathy treated at Yulin Traditional Chinese Medicine Hospital from September 2020 to September 2023 were selected for the randomized controlled trial, and were divided into a control group and an observation group by the random number table method, with 60 cases in each group. There were 42 males and 18 females in the control group; they were (49.68±5.62) years old. There were 44 males and 16 females in the observation group; they were (49.81±5.54) years old. The control group took tacrolimus, while the observation group took Jiawei Buyang Huanwu Tang and tacrolimus, for 6 months. The clinical efficacies, lipid metabolism levels [total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL)], renal function [24-hour urinary total protein (24 h-UTP), serum creatinine (Scr), and blood urea nitrogen (BUN)], inflammatory markers [transforming growth factor-β1 (TGF-β1), podocyte protein (PCX), and cystatin C (CysC)], and coagulation-fibrinolysis function [tissue plasminogen activator (t-PA) and type Ⅰ plasminogen activator inhibitor [PAI-Ⅰ]) before and after the treatment, and adverse reactions were compared between the two groups. χ2 and t tests were used for the statistical analysis. Results The overall efficacy in the observation group was higher than that in the control group [95.00% (57/60) vs. 80.00% (48/60)], with a statistical difference (χ2=6.171; P<0.05). After the treatment, the levels of TC, TG, LDL, 24 h-UTP, Scr, BUN, TGF-β1, PCX, CysC, t-PA, and PAI-Ⅰ in the observation group were better than those in the control group [(4.31±0.96) mmol/L vs. (6.39±1.24) mmol/L, (1.61±0.46) mmol/L vs. (2.49±0.72) mmol/L, (1.23±0.24) mmol/L vs. (2.59±0.41) mmol/L, (0.56±0.24) g vs. (1.34±0.37) g, (82.57±7.16) μmol/L vs. (88.49±8.64) μmol/L, (6.02±1.03) mmol/L vs. (7.34±1.28) mmol/L, (235.25±14.76) ng/L vs. (301.59±17.64) ng/L, (7.11±1.42) μg/L vs. (12.24±1.78) μg/L, (0.82±0.22) mg/L vs. (1.18±0.34) mg/L, (6.88±1.07) μg/L vs. (5.42±0.97) μg/L, and (22.01±2.08) μg/L vs. (26.78±2.63) μg/L; t=10.274, 7.978, 22.174, 13.700, 4.087, 6.223, 22.341, 17.451, and 6.886, 7.831, and 11.019; all P<0.05]. There was no statistical difference in the incidence rate of adverse reactions between the two groups (P>0.05). Conclusion Jiawei Buyang Huanwu Tang and tacrolimus in the treatment of patients with idiopathic membranous nephropathy is effective, and can improve their lipid metabolism, renal function, inflammatory status, and coagulation-fibrinolysis function.